Loading
A phase 3 trial of Divarasib, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, now recruiting.
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT07541170 by Hoffmann-La Roche, with 400 participants planned, started 2026-09-30 and due to reach its primary completion in 2032-01-31. Interventions recorded: Divarasib, Pembrolizumab, Nivolumab. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.